Perusahaan téknologi médis fokus kana ngembangkeun téknologi inovatif pikeun diagnosis awal kanker, dinten ayeuna ngumumkeun hasil panilitian énggal. Hiji studi klinis kanker ati geus nunjukkeun potensi gede biomarker basis methylation DNA anyar LAM pikeun ngadeteksi carcinoma hépatocellular (HCC) Sensitipitas deteksi nyaéta 95% jeung spésifisitas 97.5%.
Dina ulikan ieu, sampel stock tina 130 subjék dikumpulkeun, kaasup: 60 subjék didiagnosis kalawan carcinoma hépatocellular (tahap I nepi ka IV), subjék 30 tanpa kasakit ati, 10 Subjék didiagnosis kasakit ati benign jeung 30 subjék didiagnosis kanker payudara, kanker kolorektal. atawa kanker paru. DNA diekstrak tina sampel, DNA ditransformasikeun ku bisulfit, sareng métilasi DNA diukur nganggo platform IvyGene. Sanggeus réngsé ngumpulkeun data jeung analisis sakabéh sampel, buta sampel pikeun ngitung kinerja tés.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of kangker colorectal samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
